A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03804554

CA209-8MH

Details and patient eligibility

About

This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab

Enrollment: 503 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• Adult male or female (≥18 years of age) patients with NSCLC
• Treated with nivolumab on the Australian PAP
• Initiated Nivolumab between May 2015 and August 2017
• Attending clinician agreeable to provide patient data
• Local institutional ethics requirements satisfied

Exclusion Criteria:

• Insufficient data available

Other protocol defined inclusion/exclusion criteria could apply

Trial design

503 participants in 1 patient group

Patients taking nivolumab

Treatment:

Other: Non-Interventional